Monday, December 23, 2024
HomeTagsCOUR Pharmaceuticals

COUR Pharmaceuticals

COUR Pharmaceuticals Receives FDA Fast Track Designation for CNP-104 for the Treatment of Primary Biliary Cholangitis

COUR Pharmaceuticals, a biotechnology company developing novel immune-modifying nanoparticles (CNPs) to treat immune disorders, today announced the U.S. Food and Drug Administration (FDA) granted...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics